Goldman Sachs Group Inc Roivant Sciences Ltd. Transaction History
Goldman Sachs Group Inc
- $605 Billion
- Q3 2024
A detailed history of Goldman Sachs Group Inc transactions in Roivant Sciences Ltd. stock. As of the latest transaction made, Goldman Sachs Group Inc holds 5,392,375 shares of ROIV stock, worth $57.3 Million. This represents 0.01% of its overall portfolio holdings.
Number of Shares
5,392,375
Previous 4,201,335
28.35%
Holding current value
$57.3 Million
Previous $44.4 Million
40.13%
% of portfolio
0.01%
Previous 0.01%
Shares
17 transactions
Others Institutions Holding ROIV
# of Institutions
312Shares Held
507MCall Options Held
1.26MPut Options Held
2.52M-
Sb Investment Advisers (Uk) LTD London, X065.9MShares$701 Million6.27% of portfolio
-
Qvt Financial LP New York, NY65.8MShares$699 Million73.2% of portfolio
-
Viking Global Investors LP54.1MShares$575 Million2.42% of portfolio
-
Vanguard Group Inc Valley Forge, PA41.7MShares$443 Million0.01% of portfolio
-
Black Rock Inc. New York, NY35.4MShares$376 Million0.01% of portfolio
About Roivant Sciences Ltd.
- Ticker ROIV
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 704,382,976
- Market Cap $7.49B
- Description
- Roivant Sciences Ltd., a biopharmaceutical and healthcare technology company that researches and develops medicines. The company develops product candidates for the treatment of various therapeutics, including solid tumors, sickle cell diseases, hypophosphatasia, oncologic malignancies, psoriasis, atopic dermatitis, vitiligo, hyperhidrosis, acne...